Impaired Pulmonary Arterial Vasoconstriction and Nitric Oxide–Mediated Relaxation Underlie Severe Pulmonary Hypertension in the Sugen-Hypoxia Rat Model
暂无分享,去创建一个
H. Hudalla | Jun Li | S. Kourembanas | R. Khalil | H. Christou | J. S. Possomato‐Vieira | C. Dias-Junior | Z. Michael | Minglin Zhu | E. J. Filatava | E. Filatava
[1] M. Humbert,et al. Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension , 2017, The Journal of Pharmacology and Experimental Therapeutics.
[2] R. Khalil,et al. Protein Kinase C as Regulator of Vascular Smooth Muscle Function and Potential Target in Vascular Disorders. , 2017, Advances in pharmacology.
[3] N. Voelkel,et al. Endothelial hyperpermeability in severe pulmonary arterial hypertension: role of store-operated calcium entry. , 2016, American journal of physiology. Lung cellular and molecular physiology.
[4] D. Stewart,et al. Marked Strain-Specific Differences in the SU5416 Rat Model of Severe Pulmonary Arterial Hypertension. , 2016, American journal of respiratory cell and molecular biology.
[5] M. Iglarz,et al. Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension , 2015, Journal of cardiovascular pharmacology.
[6] Wei Li,et al. Estrogen Receptor Subtypes Mediate Distinct Microvascular Dilation and Reduction in [Ca2+]i in Mesenteric Microvessels of Female Rat , 2015, The Journal of Pharmacology and Experimental Therapeutics.
[7] K. Stenmark,et al. The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes. , 2015, American journal of physiology. Lung cellular and molecular physiology.
[8] Wei Li,et al. Downregulation of Microvascular Endothelial Type B Endothelin Receptor Is a Central Vascular Mechanism in Hypertensive Pregnancy , 2014, Hypertension.
[9] A. Alzoubi,et al. TRPC4 inactivation confers a survival benefit in severe pulmonary arterial hypertension. , 2013, The American journal of pathology.
[10] N. Westerhof,et al. SuHx rat model: partly reversible pulmonary hypertension and progressive intima obstruction , 2013, European Respiratory Journal.
[11] G. Visner,et al. Endothelial indoleamine 2,3-dioxygenase protects against development of pulmonary hypertension. , 2013, American journal of respiratory and critical care medicine.
[12] M. Humbert,et al. Pulmonary arterial hypertension , 2013, Orphanet Journal of Rare Diseases.
[13] C. O’Donnell. Severe pulmonary arterial hypertension , 2013, Radiopaedia.org.
[14] R. Khalil,et al. Molecular Mechanisms Regulating the Vascular Prostacyclin Pathways and Their Adaptation during Pregnancy and in the Newborn , 2012, Pharmacological Reviews.
[15] S. Kourembanas,et al. Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension. , 2012, American journal of physiology. Lung cellular and molecular physiology.
[16] K. Hunter,et al. Pulmonary vascular stiffness: measurement, modeling, and implications in normal and hypertensive pulmonary circulations. , 2011, Comprehensive Physiology.
[17] L. Shimoda,et al. Enhancement of myofilament calcium sensitivity by acute hypoxia in rat distal pulmonary arteries. , 2011, American journal of physiology. Lung cellular and molecular physiology.
[18] N. Voelkel,et al. Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial Hypertension , 2010, Circulation.
[19] A. Tonelli,et al. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. , 2010, Respiratory medicine.
[20] Sally H Vitali,et al. Impaired Vasoconstriction and Nitric Oxide-Mediated Relaxation in Pulmonary Arteries of Hypoxia- and Monocrotaline-Induced Pulmonary Hypertensive Rats , 2010, Journal of Pharmacology and Experimental Therapeutics.
[21] Kurt R Stenmark,et al. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. , 2009, American journal of physiology. Lung cellular and molecular physiology.
[22] A. Pries,et al. Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease* , 2009, Critical care medicine.
[23] Mario J. Garcia,et al. Evaluation of pulmonary artery stiffness in pulmonary hypertension with cardiac magnetic resonance. , 2009, JACC. Cardiovascular imaging.
[24] J. Stehlik,et al. Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure. , 2009, Journal of cardiac failure.
[25] C. Burger. Pulmonary Hypertension in COPD: A Review and Consideration of the Role of Arterial Vasodilators , 2009, COPD.
[26] R. Khalil,et al. Differential [Ca2+]i signaling of vasoconstriction in mesenteric microvessels of normal and reduced uterine perfusion pregnant rats. , 2008, American journal of physiology. Regulatory, integrative and comparative physiology.
[27] M. Skokan,et al. Evidence for cell fusion is absent in vascular lesions associated with pulmonary arterial hypertension. , 2008, American journal of physiology. Lung cellular and molecular physiology.
[28] M. Oka,et al. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension , 2008, British journal of pharmacology.
[29] Robin Shandas,et al. Changes in the structure-function relationship of elastin and its impact on the proximal pulmonary arterial mechanics of hypertensive calves. , 2008, American journal of physiology. Heart and circulatory physiology.
[30] C. Knoderer,et al. Use of Sildenafil to Facilitate Weaning From Inhaled Nitric Oxide in Children With Pulmonary Hypertension Following Surgery for Congenital Heart Disease , 2008, Journal of intensive care medicine.
[31] M. Oka,et al. Endothelin-1 and Serotonin are Involved in Activation of RhoA/Rho Kinase Signaling in the Chronically Hypoxic Hypertensive Rat Pulmonary Circulation , 2007, Journal of cardiovascular pharmacology.
[32] S. Archer,et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted , 2007, Proceedings of the National Academy of Sciences.
[33] Kurt R Stenmark,et al. Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. , 2007, American journal of physiology. Lung cellular and molecular physiology.
[34] N. Voelkel,et al. Rho Kinase-Mediated Vasoconstriction Is Important in Severe Occlusive Pulmonary Arterial Hypertension in Rats , 2007, Circulation research.
[35] E. Nozik-Grayck,et al. Role of reactive oxygen species in chronic hypoxia-induced pulmonary hypertension and vascular remodeling. , 2007, Advances in experimental medicine and biology.
[36] F. Faraci,et al. Endothelium-Derived Hyperpolarizing Factor: Where Are We Now? , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[37] B. Fanburg,et al. Hypoxia and hypoxia-inducible factor-1alpha promote growth factor-induced proliferation of human vascular smooth muscle cells. , 2006, American journal of physiology. Heart and circulatory physiology.
[38] R. Khalil,et al. Protein kinase C isoforms as specific targets for modulation of vascular smooth muscle function in hypertension. , 2005, Biochemical pharmacology.
[39] W. Seeger,et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.
[40] S. Archer,et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. , 2005, The Journal of clinical investigation.
[41] S. Oparil,et al. Endothelin-A Receptor Blockade Prevents and Partially Reverses Neonatal Hypoxic Pulmonary Vascular Remodeling , 2005, Pediatric Research.
[42] J. Dyck,et al. Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell Apoptosis , 2004, Circulation research.
[43] K. Morris,et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. , 2004, American journal of physiology. Lung cellular and molecular physiology.
[44] A. Stopeck,et al. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. , 2004, Leukemia research.
[45] H. Coleman,et al. Prostacyclin and endothelium-dependent hyperpolarization. , 2004, Pharmacological research.
[46] R. Marthan,et al. Role of α-Adrenergic Receptors in the Effect of the β-Adrenergic Receptor Ligands, CGP 12177, Bupranolol, and SR 59230A, on the Contraction of Rat Intrapulmonary Artery , 2004, Journal of Pharmacology and Experimental Therapeutics.
[47] R. Budhiraja,et al. Endothelial Dysfunction in Pulmonary Hypertension , 2004, Circulation.
[48] R. Marthan,et al. Role of alpha-adrenergic receptors in the effect of the beta-adrenergic receptor ligands, CGP 12177, bupranolol, and SR 59230A, on the contraction of rat intrapulmonary artery. , 2004, The Journal of pharmacology and experimental therapeutics.
[49] Larry W. Moreland,et al. Nuclear factor of activated T-cells , 2004 .
[50] W. Seeger,et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. , 2004, American journal of respiratory and critical care medicine.
[51] R. Khalil,et al. Ca2+ antagonist-insensitive coronary smooth muscle contraction involves activation of ϵ-protein kinase C-dependent pathway , 2003 .
[52] T. Phang,et al. Hypoxia induces different genes in the lungs of rats compared with mice. , 2003, Physiological genomics.
[53] R. Khalil,et al. Ca2+ antagonist-insensitive coronary smooth muscle contraction involves activation of epsilon-protein kinase C-dependent pathway. , 2003, American journal of physiology. Cell physiology.
[54] M. Yanagisawa,et al. Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats. , 2002, American journal of physiology. Lung cellular and molecular physiology.
[55] J. Dyck,et al. Dichloroacetate, a Metabolic Modulator, Prevents and Reverses Chronic Hypoxic Pulmonary Hypertension in Rats: Role of Increased Expression and Activity of Voltage-Gated Potassium Channels , 2002, Circulation.
[56] S. Narumiya,et al. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. , 2001, American journal of respiratory and critical care medicine.
[57] P. Hirth,et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[58] R. Nagai,et al. Vascular smooth muscle cell phenotypes in primary pulmonary hypertension. , 2001, The European respiratory journal.
[59] T. Jeffery,et al. Comparison of pulmonary vascular function and structure in early and established hypoxic pulmonary hypertension in rats. , 2001, Canadian journal of physiology and pharmacology.
[60] J. Granger,et al. [Ca(2+)](i) signaling in renal arterial smooth muscle cells of pregnant rat is enhanced during inhibition of NOS. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.
[61] L. Shimoda,et al. L-type Ca(2+) channels, resting [Ca(2+)](i), and ET-1-induced responses in chronically hypoxic pulmonary myocytes. , 2000, American journal of physiology. Lung cellular and molecular physiology.
[62] R. Khalil,et al. Gender-specific reduction in contractility and [Ca(2+)](i) in vascular smooth muscle cells of female rat. , 2000, American journal of physiology. Cell physiology.
[63] L. Shimoda,et al. Altered pulmonary vasoreactivity in the chronically hypoxic lung. , 2000, Physiological research.
[64] J. Granger,et al. Decreased endothelium-dependent vascular relaxation during reduction of uterine perfusion pressure in pregnant rat. , 2000, Hypertension.
[65] D. Beasley,et al. Hypoxia stimulates proliferation and interleukin-1alpha production in human vascular smooth muscle cells. , 1999, The American journal of physiology.
[66] H. Itoh,et al. Effects of the endothelin ET(A) receptor antagonist, TA-0201, on pulmonary arteries isolated from hypoxic rats. , 1999, European journal of pharmacology.
[67] N. Voelkel,et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. , 1999, The Journal of clinical investigation.
[68] R. Busse,et al. Nitric oxide, nitric oxide synthase, and hypertensive vascular disease , 1999, Current hypertension reports.
[69] C. Hsieh,et al. Prevention of Hypoxia-Induced Pulmonary Hypertension by Enhancement of Endogenous Heme Oxygenase-1 in the Rat. • 238 , 1997, Pediatric Research.
[70] R. McIntyre,et al. Mechanistic imbalance of pulmonary vasomotor control in progressive lung injury. , 1996, Surgery.
[71] P. Braquet,et al. Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. , 1991, The Journal of clinical investigation.
[72] T. Lincoln,et al. cGMP-dependent protein kinase mediates the reduction of Ca2+ by cAMP in vascular smooth muscle cells. , 1990, The American journal of physiology.
[73] B. Groves,et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. , 1989, Circulation.
[74] M. Gillespie,et al. Vascular hyperresponsiveness in perfused lungs from monocrotaline-treated rats. , 1986, The American journal of physiology.